Orgenesis (ORGS) 10-Q 15 Jul 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	May 31, 2016	Jul. 14, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	May 31, 2016
Trading Symbol	orgs
Entity Registrant Name	Orgenesis Inc.
Entity Central Index Key	1,460,602
Current Fiscal Year End Date	--11-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		110,732,129
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2016	Nov. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 474	$ 4,168
Accounts receivable	1,712	1,173
Prepaid expenses and other receivables	1,117	1,118
Grants receivable	1,431	1,446
Inventory	413	301
Total current assets	5,147	8,206
NON CURRENT ASSETS:
Property and equipment, net	4,787	4,296
Restricted cash	5	5
Intangible assets, net	16,683	16,653
Goodwill	10,059	9,535
Other assets	65	53
Total non current assets	31,599	30,542
TOTAL ASSETS	36,746	38,748
CURRENT LIABILITIES:
Accounts payable	4,209	3,475
Accrued expenses	975	816
Employee and related payables	1,947	1,348
Related parties	42	42
Advance payments on account of grant	136	307
Short-term loans and current maturities of long term loans	1,249	2,829
Deferred income	1,617	1,216
Convertible loans	2,199	3,022
Convertible bonds	1,859	1,888
Price protection derivative	175	1,533
TOTAL CURRENT LIABILITIES	14,408	16,476
LONG-TERM LIABILITIES:
Loans payable	2,514	2,540
Warrants	1,730	1,382
Retirement benefits obligation	5	5
Deferred taxes	2,562	3,327
TOTAL LONG-TERM LIABILITIES	6,811	7,254
TOTAL LIABILITIES	21,219	23,730
COMMITMENTS
REDEEMABLE COMMON STOCK	0	21,458
EQUITY (CAPITAL DEFICIENCY):
Common stock	11	6
Additional paid-in capital	39,402	14,229
Receipts on account of shares to be allotted	623	1,251
Accumulated other comprehensive loss	(202)	(1,286)
Accumulated deficit	(24,307)	(20,640)
TOTAL EQUITY (CAPITAL DEFICIENCY)	15,527	(6,440)
TOTAL LIABILITIES AND EQUITY (NET OF CAPITAL DEFICIENCY)	$ 36,746	$ 38,748

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2016	May 31, 2015
REVENUES	$ 1,132	$ 820	$ 2,652	$ 820
COST OF REVENUES	1,964	973	3,444	973
GROSS PROFIT (LOSS)	(832)	(153)	(792)	(153)
RESEARCH AND DEVELOPMENT EXPENSES, net	486	290	887	465
AMORTIZATION OF INTANGIBLE ASSETS	482	393	810	393
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	2,173	1,200	3,339	1,858
OPERATING LOSS	3,973	2,036	5,828	2,869
FINANCIAL EXPENSES (INCOME), net	553	(924)	(1,219)	(967)
LOSS BEFORE INCOME TAXES	4,526	1,112	4,609	1,902
INCOME TAX BENEFIT	(634)	(15)	(942)	(15)
NET LOSS	$ 3,892	$ 1,097	$ 3,667	$ 1,887
LOSS PER SHARE:
Basic	$ 0.04	$ 0.02	$ 0.03	$ 0.03
Diluted	$ 0.04	$ 0.03	$ 0.04	$ 0.05
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE:
Basic	107,583,871	55,785,407	106,693,858	55,760,675
Diluted	107,583,871	62,795,145	106,693,858	60,159,549
OTHER COMPREHENSIVE LOSS:
Net loss	$ 3,892	$ 1,097	$ 3,667	$ 1,887
Translation adjustments	(580)	458	(1,084)	560
TOTAL COMPREHENSIVE LOSS	$ 3,312	$ 1,555	$ 2,583	$ 2,447

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY/EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Receipts on Account of Share to be Allotted [Member]	Accumulated Other Comprehensive Loss[Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Nov. 30, 2014	$ 6	$ 13,152	$ 60	$ (18)	$ (16,179)	$ (2,979)
Beginning Balance (Shares) at Nov. 30, 2014	55,970,565
Stock-based compensation to employees and directors		321				321
Stock-based compensation to service providers		57				57
Comprehensive loss for the period				(560)	(1,887)	(2,447)
Ending Balance at May. 31, 2015	$ 6	13,530	60	(578)	(18,066)	(5,048)
Ending Balance (Shares) at May. 31, 2015	55,970,565
Beginning Balance at Nov. 30, 2015	$ 6	14,229	1,251	(1,286)	(20,640)	(6,440)
Beginning Balance (Shares) at Nov. 30, 2015	55,835,950
Stock-based compensation to employees and directors		865				865
Stock-based compensation to service providers		792				792
Warrants and shares to be issued due to extinguishment of a convertible loan		114				114
Issuance of shares from investments and conversion of convertible loans	$ 1	1,948	(1,251)			698
Issuance of shares from investments and conversion of convertible loans (Shares)	10,502,132
Reclassification of redeemable common stock	$ 4	21,454				21,458
Reclassification of redeemable common stock (Shares)	42,401,724
Receipts on account of shares to be allotted			623			623
Comprehensive loss for the period				1,084	(3,667)	(2,583)
Ending Balance at May. 31, 2016	$ 11	$ 39,402	$ 623	$ (202)	$ (24,307)	$ 15,527
Ending Balance (Shares) at May. 31, 2016	108,739,806

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	May 31, 2016	May 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,667)	$ (1,887)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,657	378
Loss from extinguishment of a convertible loan	229	0
Depreciation and amortization expenses	1,335	625
Change in fair value of warrants and embedded derivatives	(1,721)	(951)
Change in fair value of convertible bonds	(132)	(379)
Interest expense accrued on loans and convertible loans	56	224
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	(471)	210
Inccrease in inventory	(94)	(33)
Increase in other assets	(9)	0
Decrease (increase) in prepaid expenses and other accounts receivable	34	(789)
Increase in accounts payable	587	311
Increase in accrued expenses	150	101
Increase in employee and related payables	579	91
Increase in deferred income	332	601
Increase (decrease) in advance payments and receivables on account of grant	(87)	496
Decrease in deferred taxes	(944)	(15)
Net cash used in operating activities	(2,166)	(1,017)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(708)	(244)
Restricted cash	0	(5)
Acquisition of MaSTherCell, net of cash acquired	0	305
Net cash provided by (used in) investing activities	(708)	56
CASH FLOWS FROM FINANCING ACTIVITIES:
Short-term line of credit	0	(14)
Proceeds from issuance of loans payable	0	317
Proceeds from issuance of warrants into shares and warrants	975	0
Repayment of short and long-term debt	(1,828)	(67)
Net cash provided by (used in) financing activities	(853)	236
NET CHANGE IN CASH AND CASH EQUIVALENTS	(3,727)	(725)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	33	(404)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,168	1,314
CASH AND CASH EQUIVALENTS AT END OF PERIOD	474	185
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Conversion of loans (including accrued interest) to common stock and warrants	1,028	0
Reclassification of redeemable common stock to equity	21,458	0
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH	$ 143	$ 0

GENERAL AND BASIS OF PRESENTATI

GENERAL AND BASIS OF PRESENTATION	6 Months Ended
	May 31, 2016
GENERAL AND BASIS OF PRESENTATION [Text Block]	NOTE 1 - GENERAL AND BASIS OF PRESENTATION Orgenesis Inc. (“the Company”) was incorporated in the State of Nevada on June 5, 2008. The Company is developing a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. As discussed in Note 3, on March 2, 2015, the Company completed the acquisition of MaSTherCell SA and Cell Therapy Holding SA (collectively “MaSTherCell”). MaSTherCell is a Contract Development and Manufacturing Organization (“CDMO”) specializing in cell therapy development for advanced medicinal products. Cell therapy is the prevention or treatment of human disease by the administration of cells that have been selected, multiplied and pharmacologically treated or altered outside the body (ex vivo). MaSTherCell's CDMO activity is operated as a separate reporting segment (See Note 4). As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its wholly-owned subsidiaries (“Subsidiaries”). Unless otherwise specified, all amounts are expressed in United States dollars. Basis of Presentation These unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of May 31, 2016, and the consolidated statements of comprehensive loss for the three and six months ended May 31 2016 and 2015, and the changes in equity (capital deficiency) and cash flows for the six months period ended May 31, 2016 and 2015. The results for the six months ended May 31, 2016 are not necessarily indicative of the results to be expected for the year ending November 30, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2015. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of May 31, 2016, the Company had not achieved profitable operations, had accumulated losses of $24.3 million (since inception), had a negative cash flows from operating activities, had a working deficiency of $9.3 million and expects to incur further losses in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. The Company needs to raise significant funds on an immediate basis in order to continue to meet its liquidity needs, realize its business plan and maintain operations. The Company’s current cash resources are not sufficient to support its operations as presently conducted or permit it to take advantage of business opportunities that may arise. Management of the Company is continuing its efforts to secure funds through equity and/or debt instruments for its operations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that management will be successful in implementing a business plan or that the successful implementation of a business plan will actually improve the Company’s operating results. Presently, the Company does not have any financing commitment from any person, and there can be no assurance that additional capital will be available to the Company on commercially acceptable terms or at all. If the Company is unable to obtain the necessary capital, the Company may have to cease operations. The Company has been funding its operations primarily from the proceeds from the private placements of its convertible and equity securities. From December 2015 through May 2016, the Company received proceeds of approximately $975 thousand from the proceeds of the private placement to certain accredited investors of its unsecured equity stock. In addition, between June 1 and July 14, 2016, the Company raised an additional $1.4 million from the proceeds of private placement of its securities.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	May 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Text Block]	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accounting policies adopted are consistent with those of the previous financial year except as described below. Newly Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-06, Contingent Put and Call Options in Debt Instruments In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting

ACQUISITION OF MASTHERCELL

ACQUISITION OF MASTHERCELL	6 Months Ended
	May 31, 2016
ACQUISITION OF MASTHERCELL [Text Block]	NOTE 3 – ACQUISITION OF MASTHERCELL Description of the Transaction The Company entered into a share exchange agreement dated November 3, 2014, as subsequently amended (the "Share Exchange Agreement" or "SEA"), with MaSTherCell SA, Cell Therapy Holding SA (collectively “MaSTherCell”). Pursuant to the Share Exchange Agreement, which closed on March 2, 2015 in exchange for all of the issued and outstanding shares of MaSTherCell, the Company issued to the shareholders of MaSTherCell an aggregate of 42,401,724 shares (the “Consideration Shares”) of common stock at a price of $0.58 per share for an aggregate price of $24.6 million. Out of the Consideration Shares, 8,173,483 shares will be allocated to the bondholders of MaSTherCell in case of conversion. On November 12, 2015, the Company and MaSTherCell and each of the shareholders of MaSTherCell (the “MaSTherCell Shareholders”), entered into an amendment (“Amendment No. 2”) to the Share Exchange Agreement. Under Amendment No. 2, the MaSTherCell Shareholders option to unwind the transaction as contained in the original Share Exchange Agreement (the “Unwind Option”) was extended to November 30, 2015. In addition the Company agreed to remit to MaSTherCell, by way of an equity investment, the sum of EUR3.8 million by November 30, 2015 (the “Initial Investment”), to be followed by a subsequent equity investment by December 31, 2015 in MaSTherCell of EUR1.2 million. The extended right of the MaSTherCell Shareholders to unwind the transaction could have been exercised by them only if the Company had not achieved the Post Closing Financing and/or completed the Initial Investment (as defined) by November 30, 2015. In connection with the equity investment, on December 10, 2015 the Company agreed to invest EUR2.2 million in MaSTherCell equity in addition to the Initial Investment, which additional amount becomes due upon the request of the MaSTherCell board of directors, of whom Company directors/officers currently represent a majority. The Company’s agreement represents an increase of EUR1 million over the amount which the Company was previously obligated to invest in MaSTherCell under the Share Exchange Agreement as additional equity and replaces any funding obligation that the Company had under the SEA, as amended. On December 10, 2015 the Company remitted to MaSTherCell the Initial Investment of € 3.8 million or $4.1 million (out of the original obligation for investment of € 6 million), in compliance with its obligations as required under the Share Exchange Agreement. As a result, the Unwind Option was canceled and all the shares that were issued, have been reclassed from redeemable common stock into equity. During the three months ended May 31, 2016, the Company remitted to MaSTherCell an additional $328 thousand (€ 286 thousand), in compliance with its obligations. On June and July 2016, an additional $1 million (€ 896 thousand was remitted to MaSTherCell (See also Note 11).

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	May 31, 2016
SEGMENT INFORMATION [Text Block]	NOTE 4 - SEGMENT INFORMATION The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM"). Following the acquisition of MaSTherCell, management has determined that there are two operating segments, based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance. CDMO The CDMO activity is operated by MaSTherCell, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: (i) process and assay development services and (ii) GMP contract manufacturing services. The CDMO segment includes only the results of MaSTherCell. CTB The Cellular Therapy Business (“CTB”) activity is based on the technology licensed by the Israeli Subsidiary, that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. This segment is comprised of all entities aside from MaSTherCell. The Company assesses the performance based on a measure of "Adjusted EBIT" (earnings before financial expenses and tax, and excluding share-based compensation expenses and non-recurring income or expenses). The measure of assets has not been disclosed for each segment. Adjusted EBIT is a non-GAAP financial measure that the Company believes that provides useful information to investors and others in understanding and evaluating the Company's operating results in the same manner as the Company's management and board of directors. Segment data for the six months ended May 31, 2016 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 2,974 $ $ (322 ) $ 2,652 Cost of revenues (3,220 ) 299 (2,921 ) Research and development expenses, net (674 ) 23 (651 ) Operating expenses (1,065 ) (851 ) (1,916 ) Depreciation and amortization expenses (1,333 ) (2 ) (1,335 ) Segment Performance $ (2,644 ) $ (1,527 ) (4,171 ) Stock-based compensation (1,657 ) (1,657 ) Financial income (expenses), net 1,219 1,219 Loss before income taxes $ (4,609 ) Segment data for the six months ended May 31, 2015 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 951 $ $ (131 ) $ 820 Cost of revenues (743 ) (743 ) Research and development expenses, net (517 ) 131 (386 ) Operating expenses (664 ) (893 ) (1,557 ) Depreciation and amortization expense (622 ) (3 ) (625 ) Segment Performance $ (1,078 ) $ (1,413 ) (2,491 ) Stock-based compensation (378 ) (378 ) Financial income (expenses), net 967 967 Loss before income taxes $ (1,902 ) Segment data for the three months ended May 31, 2016 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 1,403 $ $ (271 ) $ 1,132 Cost of revenues (1,932 ) 180 (1,752 ) Research and development expenses, net (376 ) 91 (285 ) Operating expenses (458 ) (429 ) (887 ) Depreciation and amortization expense (693 ) (1 ) (694 ) Segment Performance $ (1,680 ) $ (806 ) (2,486 ) Share-based compensation (1,487 ) (1,487 ) Financial income (expenses), net (553 ) (553 ) Loss before income taxes $ (4,526 ) Segment data for the three months ended May 31, 2015 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 951 $ $ (131 ) $ 820 Cost of revenues (743 ) (743 ) Research and development expenses, net (290 ) 131 (159 ) Operating expenses (664 ) (534 ) (1,198 ) Depreciation and amortization expense (622 ) (3 ) (625 ) Segment Performance $ (1,078 ) $ (827 ) (1,905 ) Stock-based compensation (131 ) (131 ) Financial income (expenses), net 924 924 Loss before income taxes $ (1,112 ) Geographic, Product and Customer Information Substantially all of the Company's revenues and long lived assets are located in Belgium. Net revenues from single customers from the CDMO segment that exceed 10% of total net revenues are: Three Months Six Months Ended May 31, Ended May 31, 2016 2016 (in thousands) Customer A $ 830 $ 1,594 Customer B $ 420 $ 981 The Company has included adjusted EBIT in this Quarterly Report on Form 10-Q because it is a key measure used to evaluate the Company’s financial and operating performance, generate future operating plans and make strategic decisions for the allocation of capital. Accordingly, the Company believes that adjusted EBIT provides useful information to investors and others in understanding and evaluating the operating results in the same manner as our management and board of directors. While the Company believes that this non-GAAP financial measure is useful in evaluating its business, this information should be considered as supplemental in nature and is not meant as a substitute for the related financial information prepared in accordance with US GAAP.

CONVERTIBLE LOAN AGREEMENTS

CONVERTIBLE LOAN AGREEMENTS	6 Months Ended
	May 31, 2016
CONVERTIBLE LOAN AGREEMENTS [Text Block]	NOTE 5 – CONVERTIBLE LOAN AGREEMENTS 1) During the year ended November 30, 2015 and 2014, the Company entered into six convertible loan agreements (out of which five during 2015) with new investors for a total amount of $1 million (the “Convertible Loans”), interest is calculated at 6% annually and was payable, along with the principal on or before the maturity date. On April 27, 2016 and December 23, 2015, the holders of all the Convertible Loans and the Company agreed to convert the Convertible Loans and accrued interest into units of the Company’s common stock, each unit comprising one share of the Company’s common stock and one three-year warrant to purchase an additional share of the Company’s common stock at an exercise price of $0.52. Upon conversion of the Convertible Loans, the Company issued an aggregate of 1,976,330 shares of Common stock and three year warrants to purchase up to an additional 1,976,330 shares. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) on or before December 23, 2016, the Company will issue, for no additional consideration, additional common shares to subscribers, according to the mechanism defined in the agreements. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration. The Company allocated the principal amount of the convertible loans and the accrued interest thereon based on their fair value. The table below presents the fair value of the instruments issued as of the conversion dates and the allocation of the proceeds (for the fair value as of May 31, 2016, see Note 10): Total Fair Value (in thousands) December 23, April 27, 2015 2016 Warrants component $ 323 $ 13 Price protection derivative component 34 2 Shares component 614 32 Total $ 971 $ 47 2) On April 27, 2016, the Company entered into an assignment and assumption of debt agreement with Nine Investments Ltd. (“Nine Investments”) and Admiral Ventures Inc. (“Admiral”). Pursuant to the terms of a Convertible Loan Agreement dated May 29, 2014, as amended on December 2014 (collectively, the "Loan Agreement"), Nine Investments agreed to assign and transfer to Admiral all of the Company’s obligations for the outstanding amount of the Loan Agreement. Additional amendments to the provisions of the Loan Agreement were executed as follows: a) Extend the due date of the loan of $1.5 million through September 30, 2016; The Company accounted for the above changes as an extinguishment of the old debt and issuance of a new debt. As a result, a loss of $229 thousand was recorded within financial expenses.

COMMITMENTS

COMMITMENTS	6 Months Ended
	May 31, 2016
COMMITMENTS [Text Block]	NOTE 6 – COMMITMENTS Collaboration Agreements 1) On March 14, 2016, the Israel subsidiary, entered into a collaboration agreement with CureCell Co., Ltd. (“CureCell”), initially for the purpose of applying for a grant from the Korea Israel Industrial R&D Foundation ("Koril-RDF") for pre-clinical and clinical activities related to the commercialization of Orgenesis Ltd.’s AIP cell therapy product in Korea ("Koril Grant"). Subject to receiving the Koril Grant, the Parties agreed to carry out at their own expense their respective commitments under the work plan approved by Koril-RDF and any additional work plan to be agreed between the Israeli Subsidiary and CureCell. The Israeli Subsidiary will own sole rights to any intellectual property developed from the collaboration which is derived under the Israeli Subsidiary’s AIP cell therapy product, information licensed from THM. Subject to obtaining the requisite approval needed to commence commercialization in Korea, the Israel subsidiary has agreed to grant to CureCell, or a fully owned subsidiary thereof, under a separate sub-license agreement an exclusive sub-license to the intellectual property underlying the Company’s API product solely for commercialization of the Israel subsidiary products in Korea. As part of any such license, CureCell has agreed to pay annual license fees, ongoing royalties based on net sales generated by CureCell and its sublicensees, milestone payments and sublicense fees. Under the agreement, CureCell is entitled to share in the net profits derived by the Israeli Subsidiary from world - 2) On March 14, 2016, the Company and CureCell Co., Ltd. (“CureCell”) of Korea entered into a Joint Venture Agreement (the “JVA”) pursuant to which the parties will collaborate in the contract development and manufacturing of cell therapy products in Korea. The parties intend to pursue the joint venture through a newly established Korean company (the “JV Company”) which the Company by itself, or together with a designee, will hold a 50% participating interest therein, with the remaining 50% participating interest being held by CureCell. Under the JVA, CureCell is to procure, at its sole expense, a GMP facility and appropriate staff in Korea for the manufacture of the cell therapy products. The Company will share with CureCell the Company’s know-how in the field of cell therapy manufacturing, which know-how will not include the intellectual property included in the license from the Tel Hashomer Hospital in Israel to the Israeli subsidiary. In addition, each party shall be required to perform its respective obligations according to a detailed work plan to be agreed upon by CureCell and Company within no later than 30 days following the execution of the JVA. Under the JVA, the Company and CureCell each undertook to remit, within two years of the execution of the JVA, $2 million to the JV Company, of which $1 million is to be in cash and the balance in an in-kind investment, the scope and valuation of which shall be preapproved in writing by CureCell and the Company. The Company’s funding will be made by way of a convertible loan to the JV Company or the joint venture (if the JV Company is not established). The JVA provides that, under certain specified conditions, the Company can require CureCell to sell to the Company its participating (including equity) interest in the JV Company in consideration for the issuance of the Company’s common stock based on the then valuation of the JV Company. 3) On May 10, 2016 (the “Effective Date”), the Company and Atvio Biotech Ltd., a newly formed Israeli company (“Atvio”) entered into a Joint Venture Agreement (the “JVA”) pursuant to which the parties agreed to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine in the State of Israel. The parties intend to pursue the joint venture through Atvio, in which the Company will have a 50% participating interest therein. Under the JVA, Atvio is to procure, at its sole expense, a GMP facility and appropriate staff in Israel. The Company will share with Atvio the Company’s know-how in the field of cell therapy manufacturing, which know-how will not include the intellectual property included in the license from the Tel Hashomer Hospital in Israel to the Israeli Subsidiary. The parties are to create a mutually agreeable work plan within 60 days following the execution of the JVA, detailing each party’s respective obligations. Subject to the adoption of a work plan acceptable to the Company, the Company shall remit to Atvio $1 million to defray the costs associated with the setting up and the maintenance of the GMP facility, all or part of which may be contributed by way of in kind services as agreed to in the work plan. The Company’s funding will be made by way of a convertible loan to Atvio, which shall be convertible at the Company’s option at any time into 50% of the then outstanding equity capital immediately following such conversion. In addition, within a year from the Effective Date the Company has the option to require the Atvio shareholders to transfer the Company the entirety of their interest in Atvio for the consideration specified in the agreement. Within three years from the Effective Date, the Atvio shareholders shall have the option to require the Company to purchase from Atvios' shareholders their entire interest in Atvio for the consideration specified in the agreement. As of May 31, 2016, no activities have begun in Atvio. Grants 1) On April 2016, the Belgian Subsidiary received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budgeted EUR1,304 thousand support program for the development of a potential cure for Type 1 Diabetes. The financial support is awarded to the Belgium subsidiary as a recoverable advance payment at 55% of budgeted costs, or for a total of EUR717 thousand ($800 thousand). The grant will be paid to Orgenesis over the project period. 2) On May 26, 2016, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell. KORIL will give a conditional grant of up to $400 thousand each (according to terms defined in the agreement), for a joint research and development project for the use of Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes (the “Project”). The Project started on June 1, 2016. Upon the conclusion of product development, the grant shall be repaid at the yearly rate of 2.5% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period of 18 months starting on June 1, 2016. On June 2016, the Israeli Subsidiary received $160 thousand under the grant.

EQUITY

EQUITY	6 Months Ended
	May 31, 2016
EQUITY [Text Block]	NOTE 7 – EQUITY a. Share Capital The Company’s common shares are traded on the OTC Market Group’s OTCQB tier under the symbol “ORGS”. b. Financings During the six months ended May 31, 2016, the Company entered into definitive agreements with accredited and other qualified investors relating to a private placement (the “Private Placement”) of (i) 1,875,002 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 1,875,002 shares of the Company’s Common Stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $975 thousand. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) within a year from the issuance date, the Company will issue, for no additional consideration, additional common shares to subscribers in the $0.52 per share which total each subscriber’s subscription proceeds divided by the New Issuance Price, minus the number of shares already issued to such subscriber. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration (See also Note 10). The Company allocated the proceeds from the private placement based on the fair value of the warrants and the price protection derivative components. The residual amount was allocated to the shares. The table below presents the fair value of the instruments issued as of the closing dates and the allocation of the proceeds (for the fair value as of May 31, 2016, see Note 10): Total Fair Value (in thousands) Warrants component $ 265 Price protection derivative component 37 Shares component 673 Total $ 975

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
	May 31, 2016
STOCK BASED COMPENSATION [Text Block]	NOTE 8 – STOCK BASED COMPENSATION a. Options Granted to Employees and Directors On April 27, 2016, the Company approved an aggregate of 1,104,950 stock options to the Company’s Chief Executive Officer that are exercisable at $0.0001 per share and an aggregate of 1,641,300 stock options to the Chief Executive Officer of the U.S. Subsidiary that are exercisable at $.0.28 per share. The options vested immediately with a fair value as of the date of grant of $622 thousand using the Black-Scholes valuation model. b. Options Granted to Consultant On March 1, 2016 the Company entered into a consulting agreement for professional services for a period of one year. Under the terms of the agreement, the Company granted to a consultant 1 million options exercisable at $0.30 per share. The options shall vest quarterly over a period of one year, but shall immediately vest prior to such one-year period if there is an acquisition of 40% or more of the Company or upon funding of $5 million or more in financing. The fair value of those options as of the date of grant was $187 thousand using the Black-Scholes valuation model. c. Shares Issued to Consultants 1) On March 1, 2016, the Company entered into a consulting agreement for professional services for a period of one year. Under the terms of the agreement, the Company agreed to grant the consultant 250 thousand shares of restricted common stock. The fair value of the Company’s common stock as of the date of grant was $0.30. In addition, the Company will pay a retainer fee of $10,000 per month, consisting $5,000 cash per month and $5,000 shall be payable in shares of the Company’s common stock at a value equal to the price paid for the equity capital raise of at least $3 million (the “financing”). The cash fee per month and shares shall be issued upon completion of the financing. As of May 31, 2016, the financing was not completed and, therefore, no expenses were recorded in connection with the shares. 2) On April 27, 2016, the Company entered into a consulting agreement for professional services for a period of one year with two consultants. Under the terms of the agreements, the Company agreed to grant the consultants an aggregage of 1.2 million shares of restricted common stock that vested on grant date. The fair value of the Company’s common stock as of the date of grant was $0.28. 3) On May 1, 2016, the Company entered into a consulting agreement for professional services for a period of one year. Under the terms of the agreement, the Company agreed to grant a consultant 1 million shares of restricted common stock, of which the first 350,000 shares will vest immediately, 350,000 shares are to vest 90 days following the agreement date and 300,000 shares are schedule to vest 180 following the agreement date. The fair value of the Company’s common stock as of the date of grant of the first tranche was $0.28. With respect to each subsequent tranche, the fair value of the Company’s common stock as of May 31, 2016, was $0.35.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	May 31, 2016
LOSS PER SHARE [Text Block]	NOTE 9 – LOSS PER SHARE The following table sets forth the calculation of basic and diluted earnings (loss) per share for the periods indicated: Three Months Ended Six Months Ended May 31, May 31, 2016 2015 2016 2015 (in thousands, except per share data) Basic: Loss for the period $ 3,892 $ 1,097 $ 3,667 $ 1,887 Weighted average number of common 107,583,871 55,785,407 106,693,858 55,760,675 Loss per common share $ 0.04 $ 0.02 $ 0.03 $ 0.03 Diluted Loss for the period $ 3,892 $ 1,097 $ 3,667 $ 1,887 Changes in fair value of embedded 592 92 560 Change in fair value of warrants 380 526 Loss for the period 3,892 2,069 $ 3,759 2,973 Weighted average number of shares 107,583,871 55,785,407 106,693,858 55,760,675 Number of dilutive shares related to convertible 6,554,728 3,894,438 Number of dilutive shares related to warrants 455,010 504,436 Weighted average number of common shares 107,583,871 62,795,145 106,693,858 60,159,549 Loss per common share $ 0.04 $ 0.03 $ 0.04 $ 0.05 Diluted loss per share does not include 16,954,564 shares underlying outstanding options, 19,769,959 shares issuable upon exercise of warrants, 1,150,000 shares due to stock-based compensation to service providers and 4,793,603 shares upon conversion of convertible notes for the six and three months ended May 31, 2016, because the effect of their inclusion in the computation would be anti-dilutive. Diluted loss per share does not include 42,401,724 redeemable common stock, 15,367,559 shares underlying outstanding options, 350,000 shares due to stock-based compensation to service providers, 2,682,256 shares issuable upon exercise of warrants for the six and three months ended May 31, 2015, because the effect of their inclusion in the computation would be anti-dilutive.

FAIR VALUE PRESENTATION

FAIR VALUE PRESENTATION	6 Months Ended
	May 31, 2016
FAIR VALUE PRESENTATION [Text Block]	NOTE 10 - FAIR VALUE PRESENTATION The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, to the extent possible, and considers credit risk in its assessment of fair value. As of May 31, 2016 and November 30, 2015 the Company’s liabilities that are measured at fair value and classified as level 3 fair value are as follows (in thousands): May 31, November 30, 2016 2015 Level 3 Level 3 Warrants (1) $ 1,730 $ 1,382 Price protection derivative (1) 175 1,533 Embedded derivatives*(1) 260 289 Convertible bonds (2) $ 1,859 $ 1,888 * The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans). ( 1) The fair value of the warrants, price protection derivatives and embedded derivatives is determined by using a Monte Carlo Simulation Model. This model, in contrast to a closed form model, such as the Black-Scholes Model, enables the Company to take into consideration the conversion price changes over the conversion period of the loan, and therefore is more appropriate in this case. ( 2) The fair value of the convertible bonds described in Note 7 of the Annual Report is determined by using a binomial model for the valuation of the embedded derivative and the fair value of the bond was calculated based on the effective rate on the valuation date ( 6%). The binomial model used the forecast of the Company share price during the convertible bond's contractual term. Since the convertible bond is in Euro and the model is in USD, the Company has used the Euro/USD forward rates for each period. In order to solve for the embedded derivative fair value, the calculation was performed as follows: • Stage A - The model calculates a number of potential future share prices of the Company based on the volatility and risk-free interest rate assumptions. • Stage B - the embedded derivative value is calculated "backwards" in a way that takes into account the maximum value between holding the bonds until maturity or converting the bonds. The following table presents the assumptions that were used for the models as of May 31, 2016: Price Protection Derivative and Embedded Warrants Derivative Fair value of shares of common stock $0.35 $0.35 Expected volatility 88%- 91% 91% Discount on lack of marketability 14% - Risk free interest rate 0.27% - 1.03% 0.39% Expected term (years) 2.4 - 3 0.33 Expected dividend yield 0% 0% Expected capital raise dates Q3 2016, Q1 - 2018 The fair value of the convertible bonds is equal to their principal amount and the aggregate accrued interest. The following table presents the assumptions that were used for the models as of November 30, 2015: Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87%- 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44%- 1.24% 0.11%- 0.49% 0.42% Expected term (years) 0.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q 4 2016, Q4 2017 - - The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the six months ended May 31, 2016: Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the period $ 1,382 $ 289 $ 1,888 $ 1,533 Additions 601 73 Conversion (10 ) Changes in fair value during the period (253 ) (11 ) (132 ) (1,431 ) Changes in fair value due to extinguishment of convertible loan (8 ) Translation adjustments 103 Balance at end of the period $ 1,730 $ 260 $ 1,859 $ 175 There were no transfers to Level 3 during the three months ended May 31, 2016. The Company has performed a sensitivity analysis of the results for the warrants fair value to changes in the assumptions for expected volatility with the following parameters: Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 1,499 $ 1,730 $ 1,949 The Company has performed a sensitivity analysis of the results for the price protection derivative fair value to changes in the assumptions expected volatility with the following parameters: Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 174 $ 175 $ 177 The Company has performed a sensitivity analysis of the results for the Embedded Derivative fair value to changes in the assumptions expected volatility with the following parameters: Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 222 $ 260 $ 298 The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2015: Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ $ Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) 7 Changes in fair value during the period (43 ) (814 ) (1,221 ) Translation adjustments (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533 (*) During the twelve months ended November 30, 2015, 1,826,718 warrants had expired. There were no transfers to Level 3 during the twelve months ended November 30, 2015.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	May 31, 2016
SUBSEQUENT EVENTS [Text Block]	NOTE 11 - SUBSEQUENT EVENTS In June and July 2016, the Company entered into several unsecured convertible note agreements with accredited or offshore investors for an aggregate amount of $877.5 thousand. The term of the notes is for two years with an interest rate of 6% per annum. The entire principal amount under the notes and accrued interest shall automatically convert into “Units” (as defined below) upon the earlier to occur of any of the following: (i) the closing of an offering of equity securities of the Company with gross proceeds to the Company greater than $10 million (“Qualified Offering”) (ii) the trading of the Company’s common stock on the over-the counter market or an exchange at a weighted average price of at least $0.52 for fifty (50) consecutive trading days, or (iii) the listing of the Company’s Common Stock on a U.S. National Exchange (each a “Conversion Event”). Each $0.52 of principal amount and accrued interest due shall convert into (a “Unit”), consisting of one share of Common Stock and one three-year warrant exercisable into an additional share of common stock at a per share exercise price of $0.52, provided that, if more favorable to the holder, any principal amount and accrued interest due shall convert into securities on the same basis as such securities are sold in the Qualified Offering. At any time, the holder may convert the principal amount and accrued interest outstanding into Units as provided above. In addition, if a Conversion Event does not occur within 12 months of the issuance date hereof, then the holder, at its option, may convert the outstanding principal amount and accrued interest under this note into either (i) Units as provided above, or (ii) shares of the Company’s common stock at a per share conversion price of $0.40. In June and July 2016, the Company entered into definitive agreements with accredited investors relating to a private placement (the “Private Placement”) of (i) 1,004,807 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 1,004,807 shares of the Company’s Common Stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $522.5 thousand. Furthermore, in certain events (according to terms defined in the agreements) the Company will issue, for no additional consideration, additional common shares to subscribers which total each Subscriber’s subscription proceeds divided by the New Issuance Price, minus the number of shares already issued to such subscriber. From the above investments, the Company remitted to MaSTherCell $1 million (€ 896 thousand, in compliance with its obligations.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	May 31, 2016
Newly Issued Accounting Pronouncements [Policy Text Block]	Newly Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-06, Contingent Put and Call Options in Debt Instruments In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended		6 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2016	May 31, 2015
Schedule of Segment Information [Table Text Block]	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 1,403 $ $ (271 ) $ 1,132 Cost of revenues (1,932 ) 180 (1,752 ) Research and development expenses, net (376 ) 91 (285 ) Operating expenses (458 ) (429 ) (887 ) Depreciation and amortization expense (693 ) (1 ) (694 ) Segment Performance $ (1,680 ) $ (806 ) (2,486 ) Share-based compensation (1,487 ) (1,487 ) Financial income (expenses), net (553 ) (553 ) Loss before income taxes $ (4,526 )	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 951 $ $ (131 ) $ 820 Cost of revenues (743 ) (743 ) Research and development expenses, net (290 ) 131 (159 ) Operating expenses (664 ) (534 ) (1,198 ) Depreciation and amortization expense (622 ) (3 ) (625 ) Segment Performance $ (1,078 ) $ (827 ) (1,905 ) Stock-based compensation (131 ) (131 ) Financial income (expenses), net 924 924 Loss before income taxes $ (1,112 )	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 2,974 $ $ (322 ) $ 2,652 Cost of revenues (3,220 ) 299 (2,921 ) Research and development expenses, net (674 ) 23 (651 ) Operating expenses (1,065 ) (851 ) (1,916 ) Depreciation and amortization expenses (1,333 ) (2 ) (1,335 ) Segment Performance $ (2,644 ) $ (1,527 ) (4,171 ) Stock-based compensation (1,657 ) (1,657 ) Financial income (expenses), net 1,219 1,219 Loss before income taxes $ (4,609 )	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 951 $ $ (131 ) $ 820 Cost of revenues (743 ) (743 ) Research and development expenses, net (517 ) 131 (386 ) Operating expenses (664 ) (893 ) (1,557 ) Depreciation and amortization expense (622 ) (3 ) (625 ) Segment Performance $ (1,078 ) $ (1,413 ) (2,491 ) Stock-based compensation (378 ) (378 ) Financial income (expenses), net 967 967 Loss before income taxes $ (1,902 )
Schedule of Revenues from Major Customers [Table Text Block]			Three Months Six Months Ended May 31, Ended May 31, 2016 2016 (in thousands) Customer A $ 830 $ 1,594 Customer B $ 420 $ 981

CONVERTIBLE LOAN AGREEMENTS (Ta

CONVERTIBLE LOAN AGREEMENTS (Tables)	6 Months Ended
	May 31, 2016
Schedule of Fair Value of Loan Agreement [Table Text Block]	Total Fair Value (in thousands) December 23, April 27, 2015 2016 Warrants component $ 323 $ 13 Price protection derivative component 34 2 Shares component 614 32 Total $ 971 $ 47

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	May 31, 2016
Schedule of Fair Value of Instruments for Financing [Table Text Block]	Total Fair Value (in thousands) Warrants component $ 265 Price protection derivative component 37 Shares component 673 Total $ 975

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	May 31, 2016
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended May 31, May 31, 2016 2015 2016 2015 (in thousands, except per share data) Basic: Loss for the period $ 3,892 $ 1,097 $ 3,667 $ 1,887 Weighted average number of common 107,583,871 55,785,407 106,693,858 55,760,675 Loss per common share $ 0.04 $ 0.02 $ 0.03 $ 0.03 Diluted Loss for the period $ 3,892 $ 1,097 $ 3,667 $ 1,887 Changes in fair value of embedded 592 92 560 Change in fair value of warrants 380 526 Loss for the period 3,892 2,069 $ 3,759 2,973 Weighted average number of shares 107,583,871 55,785,407 106,693,858 55,760,675 Number of dilutive shares related to convertible 6,554,728 3,894,438 Number of dilutive shares related to warrants 455,010 504,436 Weighted average number of common shares 107,583,871 62,795,145 106,693,858 60,159,549 Loss per common share $ 0.04 $ 0.03 $ 0.04 $ 0.05

FAIR VALUE PRESENTATION (Tables

FAIR VALUE PRESENTATION (Tables)	6 Months Ended	12 Months Ended
	May 31, 2016	Nov. 30, 2015
Schedule of Assets and Liabilities at Fair Value [Table Text Block]	May 31, November 30, 2016 2015 Level 3 Level 3 Warrants (1) $ 1,730 $ 1,382 Price protection derivative (1) 175 1,533 Embedded derivatives*(1) 260 289 Convertible bonds (2) $ 1,859 $ 1,888
Schedule of Fair Value, Assumptions Used [Table Text Block]	Price Protection Derivative and Embedded Warrants Derivative Fair value of shares of common stock $0.35 $0.35 Expected volatility 88%- 91% 91% Discount on lack of marketability 14% - Risk free interest rate 0.27% - 1.03% 0.39% Expected term (years) 2.4 - 3 0.33 Expected dividend yield 0% 0% Expected capital raise dates Q3 2016, Q1 - 2018	Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87%- 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44%- 1.24% 0.11%- 0.49% 0.42% Expected term (years) 0.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q 4 2016, Q4 2017 - -
Schedule of Sensitivity Analysis of Fair Value, Warrants [Table Text Block]	Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 1,499 $ 1,730 $ 1,949
Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives [Table Text Block]	Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 174 $ 175 $ 177
Schedule of Sensitivity Analysis of Changes in Fair Value, Embedded Derivatives [Table Text Block]	Base - 10% Base Base+ 10% (in thousands) As of May 31, 2016 $ 222 $ 260 $ 298
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block]	Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the period $ 1,382 $ 289 $ 1,888 $ 1,533 Additions 601 73 Conversion (10 ) Changes in fair value during the period (253 ) (11 ) (132 ) (1,431 ) Changes in fair value due to extinguishment of convertible loan (8 ) Translation adjustments 103 Balance at end of the period $ 1,730 $ 260 $ 1,859 $ 175	Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ $ Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) 7 Changes in fair value during the period (43 ) (814 ) (1,221 ) Translation adjustments (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533

GENERAL AND BASIS OF PRESENTA23

GENERAL AND BASIS OF PRESENTATION (Narrative) (Details) $ in Thousands	6 Months Ended
	May 31, 2016USD ($)
General And Basis Of Presentation 1	$ 24,300
General And Basis Of Presentation 2	9,300
General And Basis Of Presentation 3	975
General And Basis Of Presentation 4	$ 1,400

ACQUISITION OF MASTHERCELL (Nar

ACQUISITION OF MASTHERCELL (Narrative) (Details) - 6 months ended May 31, 2016 $ / shares in Units, € in Thousands, pure in Millions	USD ($)$ / sharesshares	EUR (€)shares
Acquisition Of Masthercell 1 | shares	42,401,724	42,401,724
Acquisition Of Masthercell 2 | $ / shares	$ 0.58
Acquisition Of Masthercell 3 | $	$ 24,600,000
Acquisition Of Masthercell 4 | shares	8,173,483	8,173,483
Acquisition Of Masthercell 5	3.8	3.8
Acquisition Of Masthercell 6	1.2	1.2
Acquisition Of Masthercell 7	2.2	2.2
Acquisition Of Masthercell 8	1	1
Acquisition Of Masthercell 9 | €		€ 3,800
Acquisition Of Masthercell 10 | $	$ 4,100,000
Acquisition Of Masthercell 11 | €		6,000
Acquisition Of Masthercell 12 | $	328,000
Acquisition Of Masthercell 13 | €		286
Acquisition Of Masthercell 14 | $	$ 1,000,000
Acquisition Of Masthercell 15 | €		€ 896

SEGMENT INFORMATION (Narrative)

SEGMENT INFORMATION (Narrative) (Details)	6 Months Ended
	May 31, 2016
Segment Information 1	10.00%

CONVERTIBLE LOAN AGREEMENTS (Na

CONVERTIBLE LOAN AGREEMENTS (Narrative) (Details)	6 Months Ended
	May 31, 2016USD ($)shares
Convertible Loan Agreements 1	$ 1,000,000
Convertible Loan Agreements 2	6.00%
Convertible Loan Agreements 3	$ 0.52
Convertible Loan Agreements 4 | shares	1,976,330
Convertible Loan Agreements 5 | shares	1,976,330
Convertible Loan Agreements 6	$ 0.52
Convertible Loan Agreements 7	$ 1,500,000
Convertible Loan Agreements 8 | shares	288,461
Convertible Loan Agreements 9	$ 0.52
Convertible Loan Agreements 10	34,000
Convertible Loan Agreements 11	0.28
Convertible Loan Agreements 12	$ 55,000
Convertible Loan Agreements 13	12.00%
Convertible Loan Agreements 14	$ 229,000

COMMITMENTS (Narrative) (Detail

COMMITMENTS (Narrative) (Details) $ in Thousands	6 Months Ended
	May 31, 2016USD ($)dmo
Commitments 1	50.00%
Commitments 2	50.00%
Commitments 3 | d	30
Commitments 4	$ 2,000
Commitments 5	$ 1,000
Commitments 6	50.00%
Commitments 7 | d	60
Commitments 8	$ 1,000
Commitments 9	50.00%
Commitments 10	1,304,000
Commitments 11	55.00%
Commitments 12	717,000
Commitments 13	$ 800
Commitments 14	$ 400
Commitments 15	2.50%
Commitments 16 | mo	18
Commitments 17	$ 160

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details)	6 Months Ended
	May 31, 2016USD ($)$ / sharesshares
Equity 1 | shares	1,875,002
Equity 2 | shares	1,875,002
Equity 3	$ 0.52
Equity 4	975,000
Equity 5	$ 0.52
Equity 6 | $ / shares	$ 0.52

STOCK BASED COMPENSATION (Narra

STOCK BASED COMPENSATION (Narrative) (Details)	6 Months Ended
	May 31, 2016USD ($)d$ / shares$ / moshares
Stock Based Compensation 1 | shares	1,104,950
Stock Based Compensation 2 | $ / shares	$ 0.0001
Stock Based Compensation 3 | shares	1,641,300
Stock Based Compensation 4 | $ / shares	$ 0.28
Stock Based Compensation 5	$ 622,000
Stock Based Compensation 6 | shares	1,000,000
Stock Based Compensation 7 | $ / shares	$ 0.30
Stock Based Compensation 8	40.00%
Stock Based Compensation 9	$ 5,000,000
Stock Based Compensation 10	$ 187,000
Stock Based Compensation 11 | shares	250,000
Stock Based Compensation 12	$ 0.30
Stock Based Compensation 13 | $ / mo	10,000
Stock Based Compensation 14	$ 5,000
Stock Based Compensation 15	5,000
Stock Based Compensation 16	$ 3,000,000
Stock Based Compensation 17 | shares	1,200,000
Stock Based Compensation 18	$ 0.28
Stock Based Compensation 19 | shares	1,000,000
Stock Based Compensation 20 | shares	350,000
Stock Based Compensation 21 | shares	350,000
Stock Based Compensation 22 | d	90
Stock Based Compensation 23 | shares	300,000
Stock Based Compensation 24	180
Stock Based Compensation 25	$ 0.28
Stock Based Compensation 26	$ 0.35

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details)	6 Months Ended
	May 31, 2016shares
Loss Per Share 1	16,954,564
Loss Per Share 2	19,769,959
Loss Per Share 3	1,150,000
Loss Per Share 4	4,793,603
Loss Per Share 5	42,401,724
Loss Per Share 6	15,367,559
Loss Per Share 7	350,000
Loss Per Share 8	2,682,256

FAIR VALUE PRESENTATION (Narrat

FAIR VALUE PRESENTATION (Narrative) (Details)	6 Months Ended
	May 31, 2016shares
Fair Value Presentation 1	6.00%
Fair Value Presentation 2	1,826,718

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - 6 months ended May 31, 2016 € in Thousands	USD ($)moshares	EUR (€)moshares
Subsequent Events 1	$ 877,500
Subsequent Events 2	6.00%	6.00%
Subsequent Events 3	$ 10,000,000
Subsequent Events 4	0.52
Subsequent Events 5	0.52
Subsequent Events 6	$ 0.52
Subsequent Events 7 | mo	12	12
Subsequent Events 8	$ 0.40
Subsequent Events 9 | shares	1,004,807	1,004,807
Subsequent Events 10 | shares	1,004,807	1,004,807
Subsequent Events 11	$ 0.52
Subsequent Events 12	522,500
Subsequent Events 13	$ 1,000,000
Subsequent Events 14 | €		€ 896

Schedule of Segment Information

Schedule of Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2016	May 31, 2015
Segment Information Schedule Of Segment Information 1			$ 2,974
Segment Information Schedule Of Segment Information 2			(322)
Segment Information Schedule Of Segment Information 3			2,652
Segment Information Schedule Of Segment Information 4			(3,220)
Segment Information Schedule Of Segment Information 5			299
Segment Information Schedule Of Segment Information 6			(2,921)
Segment Information Schedule Of Segment Information 7			(674)
Segment Information Schedule Of Segment Information 8			23
Segment Information Schedule Of Segment Information 9			(651)
Segment Information Schedule Of Segment Information 10			(1,065)
Segment Information Schedule Of Segment Information 11			(851)
Segment Information Schedule Of Segment Information 12			(1,916)
Segment Information Schedule Of Segment Information 13			(1,333)
Segment Information Schedule Of Segment Information 14			(2)
Segment Information Schedule Of Segment Information 15			(1,335)
Segment Information Schedule Of Segment Information 16			(2,644)
Segment Information Schedule Of Segment Information 17			(1,527)
Segment Information Schedule Of Segment Information 18			(4,171)
Segment Information Schedule Of Segment Information 19			(1,657)
Segment Information Schedule Of Segment Information 20			(1,657)
Segment Information Schedule Of Segment Information 21			1,219
Segment Information Schedule Of Segment Information 22			1,219
Segment Information Schedule Of Segment Information 23			$ (4,609)
Segment Information Schedule Of Segment Information 1				$ 951
Segment Information Schedule Of Segment Information 2				(131)
Segment Information Schedule Of Segment Information 3				820
Segment Information Schedule Of Segment Information 4				(743)
Segment Information Schedule Of Segment Information 5				(743)
Segment Information Schedule Of Segment Information 6				(517)
Segment Information Schedule Of Segment Information 7				131
Segment Information Schedule Of Segment Information 8				(386)
Segment Information Schedule Of Segment Information 9				(664)
Segment Information Schedule Of Segment Information 10				(893)
Segment Information Schedule Of Segment Information 11				(1,557)
Segment Information Schedule Of Segment Information 12				(622)
Segment Information Schedule Of Segment Information 13				(3)
Segment Information Schedule Of Segment Information 14				(625)
Segment Information Schedule Of Segment Information 15				(1,078)
Segment Information Schedule Of Segment Information 16				(1,413)
Segment Information Schedule Of Segment Information 17				(2,491)
Segment Information Schedule Of Segment Information 18				(378)
Segment Information Schedule Of Segment Information 19				(378)
Segment Information Schedule Of Segment Information 20				967
Segment Information Schedule Of Segment Information 21				967
Segment Information Schedule Of Segment Information 22				$ (1,902)
Segment Information Schedule Of Segment Information 1	$ 1,403
Segment Information Schedule Of Segment Information 2	(271)
Segment Information Schedule Of Segment Information 3	1,132
Segment Information Schedule Of Segment Information 4	(1,932)
Segment Information Schedule Of Segment Information 5	180
Segment Information Schedule Of Segment Information 6	(1,752)
Segment Information Schedule Of Segment Information 7	(376)
Segment Information Schedule Of Segment Information 8	91
Segment Information Schedule Of Segment Information 9	(285)
Segment Information Schedule Of Segment Information 10	(458)
Segment Information Schedule Of Segment Information 11	(429)
Segment Information Schedule Of Segment Information 12	(887)
Segment Information Schedule Of Segment Information 13	(693)
Segment Information Schedule Of Segment Information 14	(1)
Segment Information Schedule Of Segment Information 15	(694)
Segment Information Schedule Of Segment Information 16	(1,680)
Segment Information Schedule Of Segment Information 17	(806)
Segment Information Schedule Of Segment Information 18	(2,486)
Segment Information Schedule Of Segment Information 19	(1,487)
Segment Information Schedule Of Segment Information 20	(1,487)
Segment Information Schedule Of Segment Information 21	(553)
Segment Information Schedule Of Segment Information 22	(553)
Segment Information Schedule Of Segment Information 23	$ (4,526)
Segment Information Schedule Of Segment Information 1		$ 951
Segment Information Schedule Of Segment Information 2		(131)
Segment Information Schedule Of Segment Information 3		820
Segment Information Schedule Of Segment Information 4		(743)
Segment Information Schedule Of Segment Information 5		(743)
Segment Information Schedule Of Segment Information 6		(290)
Segment Information Schedule Of Segment Information 7		131
Segment Information Schedule Of Segment Information 8		(159)
Segment Information Schedule Of Segment Information 9		(664)
Segment Information Schedule Of Segment Information 10		(534)
Segment Information Schedule Of Segment Information 11		(1,198)
Segment Information Schedule Of Segment Information 12		(622)
Segment Information Schedule Of Segment Information 13		(3)
Segment Information Schedule Of Segment Information 14		(625)
Segment Information Schedule Of Segment Information 15		(1,078)
Segment Information Schedule Of Segment Information 16		(827)
Segment Information Schedule Of Segment Information 17		(1,905)
Segment Information Schedule Of Segment Information 18		(131)
Segment Information Schedule Of Segment Information 19		(131)
Segment Information Schedule Of Segment Information 20		924
Segment Information Schedule Of Segment Information 21		924
Segment Information Schedule Of Segment Information 22		$ (1,112)

Schedule of Revenues from Major

Schedule of Revenues from Major Customers (Details)	6 Months Ended
	May 31, 2016USD ($)
Segment Information Schedule Of Revenues From Major Customers 1	$ 830
Segment Information Schedule Of Revenues From Major Customers 2	1,594
Segment Information Schedule Of Revenues From Major Customers 3	420
Segment Information Schedule Of Revenues From Major Customers 4	$ 981

Schedule of Fair Value of Loan

Schedule of Fair Value of Loan Agreement (Details)	6 Months Ended
	May 31, 2016USD ($)
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 1	$ 323
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 2	13
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 3	34
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 4	2
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 5	614
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 6	32
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 7	971
Convertible Loan Agreements Schedule Of Fair Value Of Loan Agreement 8	$ 47

Schedule of Fair Value of Instr

Schedule of Fair Value of Instruments for Financing (Details)	6 Months Ended
	May 31, 2016USD ($)
Equity Schedule Of Fair Value Of Instruments For Financing 1	$ 265
Equity Schedule Of Fair Value Of Instruments For Financing 2	37
Equity Schedule Of Fair Value Of Instruments For Financing 3	673
Equity Schedule Of Fair Value Of Instruments For Financing 4	$ 975

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details)	6 Months Ended
	May 31, 2016USD ($)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 1	$ 3,892
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 2	1,097
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 3	3,667
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 4	1,887
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 5	107,583,871
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 6	55,785,407
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 7	106,693,858
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 8	$ 55,760,675
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 9	0.04
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 10	0.02
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 11	0.03
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 12	0.03
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 13	$ 3,892
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 14	1,097
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 15	3,667
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 16	1,887
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 17	592
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 18	92
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 19	560
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 20	380
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 21	526
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 22	3,892
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 23	2,069
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 24	3,759
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 25	2,973
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 26	107,583,871
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 27	55,785,407
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 28	106,693,858
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 29	55,760,675
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 30	6,554,728
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 31	3,894,438
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 32	455,010
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 33	504,436
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 34	107,583,871
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 35	62,795,145
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 36	106,693,858
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 37	$ 60,159,549
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 38	0.04
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 39	0.03
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 40	0.04
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 41	0.05

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities at Fair Value (Details)	6 Months Ended
	May 31, 2016USD ($)
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1	$ 1,730
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2	1,382
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 3	175
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 4	1,533
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 5	260
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 6	289
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 7	1,859
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 8	$ 1,888

Schedule of Fair Value, Assumpt

Schedule of Fair Value, Assumptions Used (Details)	6 Months Ended	12 Months Ended
	May 31, 2016USD ($)	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1	$ 0.35
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2	$ 0.35
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3	88.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4	91.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5	91.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6	14.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7	$ 0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8	0.27%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9	1.03%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10	0.39%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11	2.4
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12	$ 3
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 16	$ 0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4		87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5		98.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6		87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7		88.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8		14.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9		$ 0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10		18.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11		0.44%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12		1.24%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13		0.11%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14		0.49%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15		0.42%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 16		0.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 17		$ 3
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 18		0.08
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 19		0.87
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 20		0.8
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 21		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 22		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 23		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 24		$ 4
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 25		0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 26		$ 0

Schedule of Sensitivity Analysi

Schedule of Sensitivity Analysis of Fair Value, Warrants (Details)	6 Months Ended
	May 31, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 1	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 2	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 3	$ 1,499
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 4	1,730
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 5	$ 1,949

Schedule of Sensitivity Analy41

Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives (Details)	6 Months Ended
	May 31, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 1	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 2	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 3	$ 174
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 4	175
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 5	$ 177

Schedule of Sensitivity Analy42

Schedule of Sensitivity Analysis of Changes in Fair Value, Embedded Derivatives (Details)	6 Months Ended
	May 31, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Embedded Derivatives 1	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Embedded Derivatives 2	10.00%
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Embedded Derivatives 3	$ 222
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Embedded Derivatives 4	260
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Embedded Derivatives 5	$ 298

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities, Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	May 31, 2016	Nov. 30, 2015
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1	$ 1,382
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2	289
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3	1,888
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4	1,533
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5	601
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6	73
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7	(10)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8	(253)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9	(11)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10	(132)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11	(1,431)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12	(8)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13	103
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14	1,730
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15	260
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16	1,859
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 17	$ 175
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1		$ 560
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2		992
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3		1,390
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4		112
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5		3,234
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6		1,526
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7		(525)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8		7
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9		(43)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10		(814)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11		(1,221)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12		(125)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13		1,382
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14		289
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15		1,888
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16		$ 1,533